Citation: Zj. Bulaj et al., Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda, J LA CL MED, 136(6), 2000, pp. 482-488
Citation: Zj. Bulaj et al., Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda, BLOOD, 95(5), 2000, pp. 1565-1571
Citation: Cq. Edwards et al., Hemochromatosis: a genetic definition, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, 2000, pp. 8-11
Citation: Cq. Edwards et al., Estimate of the frequency of morbid complications of hemochromatosis, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, 2000, pp. 312-317
Citation: Cq. Edwards et al., The iron phenotype of hemochromatosis heterozygotes, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, 2000, pp. 411-418
Citation: Cq. Edwards et Jc. Barton, Hemochromatosis: problems to be solved and directions for future investigations, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, 2000, pp. 583-587
Authors:
McDonnell, SM
Preston, BL
Jewell, SA
Barton, JC
Edwards, CQ
Adams, PC
Yip, R
Citation: Sm. Mcdonnell et al., A survey of 2,851 patients with hemochromatosis: Symptoms and response to treatment, AM J MED, 106(6), 1999, pp. 619-624